Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.

Oral, Fatma; Bilgin, Emre; Bölek, Ertugrul Çagri; Yardimci, Gözde Kübra; Kiliç, Levent

Oral, Fatma; Bilgin, Emre; Bölek, Ertugrul Çagri; Yardimci, Gözde Kübra; Kiliç, Levent.

Afiliação

Oral F; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Bilgin E; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Bölek EÇ; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Yardimci GK; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Kiliç L; Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Rheumatology (Oxford) ; 58(5): 925, 2019 05 01.

Article em En | MEDLINE | ID: mdl-30809674

Assuntos

Pneumopatias; Esclerodermia Difusa; Anticorpos Monoclonais Murinos; Ciclofosfamida; Humanos; Rituximab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerodermia Difusa / Pneumopatias Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google